Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike G Chambers

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|May 21, 2008
Pharmacoeconomics in COPD: lessons for the futureHelen J Starkie, Andrew H Briggs, Mike G Chambers
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2011
Predicting EQ-5D values using the SGRQHelen J Starkie, Andrew H Briggs, Mike G Chambers, et al.
Pharmacoeconomics|June 26, 2010
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIVTeresa L Kauf, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Chronic Obstructive Pulmonary Disease|May 21, 2008
Pharmacoeconomics in COPD: lessons for the futureHelen J Starkie, Andrew H Briggs, Mike G Chambers
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2011
Predicting EQ-5D values using the SGRQHelen J Starkie, Andrew H Briggs, Mike G Chambers, et al.
Pharmacoeconomics|June 26, 2010
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIVTeresa L Kauf, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Pageof 1